An Institute Devoted to Translational Biomedical Research
Home | Contact | Links | 简体中文版
Keywords:
  About Us Research Graduate Education Cooperation and Exchange Translational Research System Technology Platforms Faculty and Staff Join Us  
Home  »  News and Events
News and Events
 
 

News Center

News and Events
Picture News
 

MicroRNA-182 Targets SMAD7 to Potentiate TGFβ-Induced Epithelial-Mesenchymal Transition and Metastasis of Cancer Cells

The TGFβ signaling plays vital roles in multiple biological processes. During cancer progression, TGFβ stimulation promotes cancer cell epithelial-mesenchymal transition (EMT) and invasiveness, as well as tumor microenvironmental remodeling. Particularly TGFβ responsiveness is critical for cancer cells to initiate osteolytic vicious cycle for bone metastasis. However, the regulation of this pathway in cancer cells has not been completely understood. One of the loose ends is the regulation of SMAD7, the inhibitory SMAD protein of TGFβ pathway. As SMAD7 transcription is induced by TGFβ, it represents a negative feedback mechanism which can be regarded as a brake to restrain TGFβ signal in physiological conditions. But it is not known whether and how cancer cells can escape such restraint of TGFβ signaling during metastasis.

Researchers from the Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai JiaoTong University School of Medicine found that in cancer cells the SMAD7-mediated TGFβ negative feedback loop is disrupted by microRNA-182 (miR-182), which potentiates TGFβ-induced EMT and metastasis microenvironment adaptation.

The researchers showed that miR-182 induction on TGFβ stimulation could abate TGFβ-induced SMAD7 expression, thus revealed the potentiating role of miR-182 in cancer cell responses to TGFβ. Moreover, they found that miR-182 is critical in TGFβ-driven EMT, invasion, as well as cancer cell-induced osteoclastogenesis, which suggested miR-182 as a new target to treat TGFβ-driven metastasis.

A paper describing this work, entitled “MicroRNA-182 Targets SMAD7 to Potentiate TGFβ-Induced Epithelial-Mesenchymal Transition and Metastasis of Cancer Cells” was published in Nature Communications on December 20th, 2016.

This research was conducted by graduate students YU Jingyi and LEI Rong under the supervision of Dr. HU Guohong at the Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine.

This research was supported by National Natural Science Foundation of China, the Ministry of Science and Technology of China, Chinese Academy of Sciences and Science and Technology Commission of Shanghai Municipality.


The proposed role of miR-182 in the TGFβ-SMAD7 circuit.
TGFβ activates the expression of microRNA-182 (miR-182), which suppresses SMAD7 protein. MiR-182 silencing leads to SMAD7 upregulation upon TGFβ treatment and prevents TGFβ-induced EMT and invasion of cancer cells. Overexpression of miR-182 promotes breast tumor invasion and TGFβ-induced osteoclastogenesis for bone metastasis.
(Image provided by Dr. HU Guohong’s group)


Key words:microRNA-182; TGFβ; SMAD7; EMT; bone metastasis

Correspondence:
Dr. HU Guohong
The Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine
E-mail: ghhu@sibs.ac.cn

 
 
Copyright 2002-2016 The Institute of Health Sciences, SIBS, CAS / SJTUSM All Rights Reserved
225 South Chongqing Road, Shanghai, 200025 P.R. China Tel: 86-21-63847798 / 54923254 Fax: 86-21-63852579
Shanghai ICP #05033115